Lipoprotein (a) Calibrator Market Report: Trends, Forecast and Competitive Analysis to 2035

Lipoprotein (a) Calibrator Market

The future of the global lipoprotein (a) calibrator market looks promising with opportunities in the hospital and laboratory markets. The global lipoprotein (a) calibrator market is expected to reach an estimated $332.8 million by 2035 from $202.6 million in 2027 with a CAGR of 9.7% from 2027 to 2035. The major drivers for this market are the increasing prevalence of cardiovascular disease cases, the rising demand for accurate lipid testing, and the growing adoption of advanced diagnostic assays.

• Lucintel forecasts that, within the type category, human serum matrix is expected to witness higher growth over the forecast period due to use of human serum matrix calibrators has allowed for better calibration of lipids.
• Within the application category, laboratory is expected to witness higher growth over the forecast period due to increased volume of lipid testing by clinical laboratories.
• In terms of regions, APAC is expected to witness the highest growth over the forecast period due to increased need for cardiovascular disease testing and growth of laboratory testing facilities.

Emerging Trends in Lipoprotein (a) Calibrator Market

It is expected that between 2025 and 2027, the lipoprotein (a) calibrator market would move from specialized reference laboratories to routine cardiovascular (CV) disease risk-Span. Multiple factors, including the harmonization of assays and a more active role of the clinical lab staff, have resulted in an increasing demand for calibrators. According to Lucintel, between 2016 and 2021, the market focus was on stand-alone calibrators. It is expected that between 2025 and 2027, the focus will be on integration of calibration services.

• Assay Standardization: In 2025, many laboratories reported mass-based Lp(a) levels according to the International Standards. In the absence of defined standards and guidelines, many laboratories reported Lp(a) levels above 50 mg/dL. Such levels may lead to unwarranted concerns and anxiety among the patients. Therefore, it is expected that between 2025 and 2027, calibrators with reduced bias and variability will be preferred.
• Automation: During the 2025-2027 period, several clinical laboratories automated Lp(a) testing using high-volume, high-throughput automated analysers. These analysers can process hundreds of samples in a shift. Suppliers of calibrators need to develop products that can be interfaced with automated systems and remain stable over long periods of time.
• Routine CV Screening: In 2025, many agencies and professional societies issued clinical practice guidelines and position statements that stressed the need for Lp(a) testing. As a result, many adults underwent Lp(a) testing. Since 20-35% of the population has elevated Lp(a) levels, and with routine CV screening in primary care, the market for Lp(a) calibrators will increase.
• Multiplex Testing: Beginning 2025, multiple cardiovascular risk panels will be combined with Lp(a) and LDL-C, e.g. apoB. The first adoption of risk panels combined with other tests will occur in 2025. From a commercial standpoint, it is important for calibrator suppliers to enhance their products to ensure that they can achieve the desired precision of the various analytes without significant variation among different lots.
• Digital Quality Management: It is likely that during the years 2025 to 2027, calibrator lots will be electronically traced along with other records. Accredited laboratories will be able to perform audits quickly if they are able to electronically trace records and prove test results.

Demand will be heightened as lipoprotein (a) is more closely evaluated and prevalently integrated into clinical practice. Regulatory constraints will ease once multiple vendors align their policies. Until then, existing vendors will retain their positions by improving continuity and controlling costs of medical testing. Lots will be traced throughout the testing process to meet quality and safety standards.

Recent Developments in the Lipoprotein (a) Calibrator Market

The market for lipoprotein (a) calibrators is expected to grow in the next few years, as many laboratories have started to shift their focus from research to diagnosis of cardiovascular conditions. In the next few years, especially between 2025 and 2027, the market is expected to gain momentum due to the development of standardized tests for measuring lipoprotein (a) and increase in the number of clinical trials in this area. During this period, market players are expected to promote the traceability and reproducibility of assays and establish collaborations with companies involved in the development of lipoprotein (a)-lowering therapies.

• Standardization of Reference Materials: In 2025, further progress was made in the alignment of lipoprotein (a) measures with International Reference Standards. In the coming years, laboratories will adopt calibrators that provide more comparison and less argumentation about units.
• Increased Clinical Trials: The phase 3 clinical study of pelacarsen (HORIZON study) of Novartis, which is expected to enroll over 8,000 participants, was ongoing in 2025. Measures to support this and other clinical studies are expected to boost the demand for lipoprotein (a) calibrators in the coming years.
• Increased Test Automation: The introduction of automated assays for measuring lipoprotein (a) by Roche in 2025 increased automation in this area. In the coming years, central laboratories of healthcare facilities will be the major consumers of these calibrators.
• Clinical Screening Adoption: The American Heart Association (AHA) published a scientific statement in 2025, endorsing the measurement of Lp(a) at least once in adult life. Further updates to clinical guidelines are expected to include Lp(a) in coronary heart disease (CHD) risk assessment. This will increase the need for routinary calibrator supply.
• Assay Localization: In 2025, calibrator manufacturers started to develop products, in line with customer demand, for molar reporting of Lp(a) in nmol/L. Suppliers that ensure uniformity and comparability of lots of reagents will be first movers to gain competitive edge.

The shift in focus from research to routine cardiovascular testing will further strengthen the position of calibrator manufacturers, especially if they offer products with traceability to reference standards, and integration with automation. Maintaining a stable and reliable supply will also help improve market position. The forecasted market outlook for the calibrator market will be positively influenced by ongoing clinical trials and reassessment of coronary heart disease (CHD) risk.

Strategic Growth Opportunities in the Lipoprotein (a) Calibrator Market

The market for lipoprotein (a) calibrators is emerging as public health guidelines encourage the use of one-time Lipoprotein (a) testing for adults and as laboratories refine their reporting standards. It is expected that from 2024 to 2026, a number of coinciding trends such as the introduction of new cardiovascular drugs, the refinement of cardiovascular disease-related diagnostics and the development of Lipoprotein (a) assays will create increased demand. Calibrator procurement will be influenced by the reliability of the calibration services provided.

• Increased Testing Demand: The recommendation by various health associations for at least one Lipoprotein (a) test for all adults has increased the number of regional laboratories offering the testing service. This has increased the number of calibrators required by hospital laboratories and larger regional testing facilities.
• Comparability of Assays: Several assay manufacturers have stated that in the near-term, they will maintain their lipoprotein (a) assays to rely on the presence of the apo (a) protein. The CDC stated that they will maintain their reference standards for lipoprotein (a) at 50 nmol/L. This standard will encourage assay manufacturers to develop calibrators to support the automated immunochemistry platforms.
• Clinical Research: The growing number of Lipoprotein (a) lowering clinical research programs has increased the need for Lipoprotein (a) calibrators to support pharmacodynamic endpoints. It is expected that research sponsors will encourage the use of Lipoprotein (a) calibrators to support the research.
• Geographic Expansion: Cardiovascular testing has begun outside of North America. In April 2025, the European Society of Cardiology (ESC) expanded their 2016 recommendation to allow for wider assessment of Lp(a), including support for the supply of local calibrators. This creates an opportunity for the expansion of other cardiovascular testing in Europe and the Middle East.
• Premium Reference Materials: The demand for simple matrix solutions has shifted to the need for more complex, commutable materials. In 2025, many suppliers increased their price for reference materials due to stricter verification requirements set by accreditation agencies. Reference materials for cardiovascular testing are expected to maintain the ability to quantify Lp(a) at a range of concentrations.

Lp(a) testing will gain wider acceptance for risk assessment and management in the cardiovascular system. These trends will enable business development focused on clinical laboratories and the cardiovascular drug development market.

Lipoprotein (a) Calibrator Market Drivers and Challenges

Lipoprotein (a) calibrators are used in laboratories to standardize the measurement of lipoprotein (a) levels. The increase in standardization of laboratories along with the focus on cost-effectiveness of reimbursement and regulation has created an market for these calibrators. Clinicians are beginning to measure lipoprotein (a) in addition to other forms of cholesterol. However, manufacturers are still having a difficult time producing these assays in an economical manner, and reimbursement for these tests remains uncertain. According to Lucintel, the future of this market is bright and continues to have barriers for adoption.

The factors responsible for driving this market include:

• Increasing Awareness of Cardiovascular Risk: In 2025, several agencies involved in developing clinical practice guidelines called for the measurement of Lp(a) at some point in a person's life. This recommendation created an increased demand for Lp(a) calibrators. During the next three to five years, we anticipate continued efforts to prevent cardiovascular disease and stroke, as well as initiatives to assess and manage cardiovascular risk at the family level. Improving access to preventive services and tests will benefit the market for calibrators.
• Standardization of Assays: There is a growing trend towards the use of molar units (e.g. nmol/L) as opposed to mass units (e.g. µg/ml) for the reporting of laboratory results. As of June 2025, many laboratories adopted the use of molar units. There is an increasing reliance on agreed upon calibrations as a result of the need for uniform results in clinical practices such as determination of action limits, performance evaluation and proficiency testing, and international multi-center studies. It is expected that in the next five years, most laboratories will use specialized calibrators.
• Advances in Technology: Improvements in automation, along with the development of high-throughput laboratory systems and particle-enhanced immunoassays, have led to the expansion of laboratory testing and increased the demand for Lp(a) testing. In 2025, a significant number of laboratories used automated systems to process thousands of patient samples. It is expected that in the next five years, further improvements in Lp(a) testing, such as reduced turnaround time and improved isoform assessment, will occur.
• Increased Lp(a) Testing: There has been an increased emphasis on the evaluation of risk factors for cardiovascular disease, which has led to the expansion of preventive cardiovascular risk screening. In 2025, it was common practice to perform Lp(a) testing as part of lifelong health assessments. It is anticipated that in the next five years, there will be an increased need for validated calibrators and QC materials for Lp(a) testing, especially for research and screening of at-risk and high-risk populations.
• Pharmaceutical Research: Investigational drugs to lower Lp(a) have stimulated the development of Lp(a) assays and related laboratory testing and support services. Many late phase clinical trials evaluate therapies to lower Lp(a) levels by at least 80%. Measurement of Lp(a) levels during these clinical trials requires specific Lp(a) assays and related reagents and supports. During the next three to five years, by virtue of larger and more phase clinical trials, additional requirements for Lp(a) assays, reagents, and related support services will occur.

The challenges facing this market include:

• Uncertainty in Reimbursement for Lp(a) Testing: In 2025, several countries did not have consistent policies for reimbursement of Lp(a) testing. Over the next three to five years, lack of consistent reimbursement will discourage routine testing and encourage laboratories to postpone the purchase of calibration reagents for Lp(a) assays, unless it is shown that such testing will help prevent cardiovascular events and reduce the overall cost of health care.
• Lack of Assay Harmonization: Different versions of apolipoprotein (a) can result in different results for the same sample when assayed by different laboratories. As of 2025, laboratories had difficulty in interpreting and integrating mass-based Lp(a) results, especially when these results influenced clinical decisions. Until harmonization of Lp(a) assays is accomplished, increasing demand for Lp(a) testing will create uncertainty for clinical research, and stimulate the use of method specific calibrators and strengthen the need for quality assurance.
• Manufacturing and Supply Chain Complexity: Complexity in manufacturing and supply chains has made it difficult to stably and reliably produce calibrators. Also, in 2025, many laboratories had multiple calibrated levels on their instruments. This led to an increased burden on the laboratory to procure and validate multiple levels. In the short-term (3-5 years), instability of raw materials, and variability in regulatory approvals would increase costs and disruptions in the supply of calibrators, especially for small laboratories and laboratories in developing countries.

The lipoprotein (a) calibrator market is also expected to grow in the coming years because of the increased focus on preventive medicine, the automation of laboratory tests, the increased research on cardiovascular diseases, and the development of new pharmaceuticals. As of now, the major restraint on this market is the lack of standardization. The lipoprotein (a) measurement and other associated laboratory tests are not widely reimbursed. The manufacturing process is complex. In the next 3-5 years, it is expected that companies would be able to produce stable and suitable calibrators for various platforms. Other factors that would improve the market for lipoprotein (a) calibrators include improved reimbursement, clearer practice guidelines, and evidence showing that measuring Lp(a) levels would help in the care of patients.

List of Lipoprotein (a) Calibrator Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies lipoprotein (a) calibrator market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the lipoprotein (a) calibrator market companies profiled in this report include-

• Randox
• Bio-Rad
• Roche
• Abbott
• Thermo Fisher
• Sekisui Diagnostics
• Diazyme Laboratories
• Sysmex
• Becton Dickinson
• Leadman Biochemistry

Lipoprotein (a) Calibrator Market by Segment

The study includes a forecast for the global lipoprotein (a) calibrator market by type, application, and region.

Lipoprotein (a) Calibrator Market by Type [Value ($M) from 2019 to 2035]:

• Human Serum Matrix
• Synthetic Matrix

Lipoprotein (a) Calibrator Market by Application [Value ($M) from 2019 to 2035]:

• Hospital
• Laboratory
• Others

Lipoprotein (a) Calibrator Market by Region [Value ($M) from 2019 to 2035]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Lipoprotein (a) Calibrator Market

The market for Lipoprotein (a) Calibrators is transitioning from a specialist's business to a more generalized, high-throughput market. This transition is largely attributed to the revision of clinical guidelines to include the risk factors posed by elevated Lp(a). The Lipoprotein (a) assay developers are expected to align their test kits to relevant standards and frameworks in the time-frame of 2025 to 2027. According to recent findings by Lucintel, redefining supplier's strategies is expected in the positive market environment.

• United States: Changes at regulatory agencies and the adoption of next-generation lipoprotein analysers by laboratories created a positive market environment in 2025. In March, Abbott expanded the geographical availability of its Alinity i Lp(a) assay, and the National Lipid Association (NLA) supported the once in a lifetime Lp(a) testing initiative. The changes noted above are likely to motivate laboratories to adopt calibrators for Lp(a) in place of homemade calibrators.
• China: The trend toward indigenous development of diagnostic products by local companies is expected to create an environment conducive for the development of Lipoprotein (a) Calibrators. In 2025, the company Mindray (China) reported that it's chemistry and immunoassay systems were in place more than 60,000 times worldwide.
• Germany: German in vitro diagnostics companies are required to comply with the EU IVDR 2022. In contrast, in September 2025, Roche expanded its Elecsys Immunoassay platform across Europe. While traceability to locally accepted reference systems remained of interest to European manufacturers. This situation could, however, change in the future, especially if most EU in vitro diagnostics companies comply with the IVDR.
• India: A growing number of public and private laboratories in India offer cardiovascular risk tests. Siemens Healthineers has a significantly large customer base in India, and in January 2025 they reported serving over 70,000 customers worldwide. It is expected that increased distribution and local reagent partnerships will create a need for Lp(a) calibrators in India.
• Japan: There is a growing trend for Japanese diagnostics companies to focus on precision and quality control. Sysmex, which has operations in 190 countries, began distributing standardized laboratory products in different countries in April 2025. There is potential for increased sales of traceable Lp(a) calibrators in Japan.

Features of the Global Lipoprotein (a) Calibrator Market

• Market Size Estimates: lipoprotein (a) calibrator market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
• Segmentation Analysis: lipoprotein (a) calibrator market size by type, application, and region in terms of value ($B).
• Regional Analysis: lipoprotein (a) calibrator market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the lipoprotein (a) calibrator market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the lipoprotein (a) calibrator market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the lipoprotein (a) calibrator market by type (human serum matrix and synthetic matrix), application (hospital, laboratory, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?